 1. Antibiotic resistance is becoming more common in important bacterial pathogens, so phage therapy, PT, which involves using bacterial viruses to infect the pathogen in a species-specific way, is being considered as an alternative. 2. To assist the safety and effectiveness of oral phage therapy, T4-like colifiges or a commercial Russian colifige product or placebo was given over 4 days to Bangladeshi children hospitalized with acute bacterial diarrhea. 3. The safety of oral phage was assessed clinically and through functional tests, including determining colifige and escharitia colititers and measuring quantitative diarrhea parameters such as stool output and frequency. 3. In addition to these tests, the study also examined the children's fecal microbiota by sequencing the 16SRRNA gene and sequencing the genomes of four fecal streptococcus isolates. 4. The results showed that no adverse events attributable to oral phage application were observed, primary safety outcome. However, while fecal colifige levels increased in treated children compared to controlled children, the titers did not show substantial intestinal phage replication, secondary microbiology outcome. 5. 60% of the children suffered from a microbiologically proven E. coli diarrhea, with the most common diagnosis being E.T.E.C. infections. Bacterial copathogens were also detected. Half of the patients contained far susceptible E. coli colonies in the stool. 6. The study found that E. coli represented less than 5% of fecal bacteria and that stool E.T.E.C. ticked. This article was authored by Shafiqul Alam Sirkar, Shamima Sultana, Gloria Riutla and others. We are article.tv, links in the description below.